170 related articles for article (PubMed ID: 15955701)
1. Automated feature assessment in instrumented gait analysis.
Wolf S; Loose T; Schablowski M; Döderlein L; Rupp R; Gerner HJ; Bretthauer G; Mikut R
Gait Posture; 2006 Apr; 23(3):331-8. PubMed ID: 15955701
[TBL] [Abstract][Full Text] [Related]
2. [Botulinum A in the treatment of equinus dynamic spasticity in children with cerebral palsy. Preliminary study].
Mousny M; Allington N
Rev Chir Orthop Reparatrice Appar Mot; 1999 May; 85(2):156-63. PubMed ID: 10392416
[TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin type A for the treatment of the spastic equinus foot in cerebral palsy.
Cardoso ES; Rodrigues BM; Barroso M; Menezes CJ; Lucena RS; Nora DB; Melo A
Pediatr Neurol; 2006 Feb; 34(2):106-9. PubMed ID: 16458821
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group.
Koman LA; Mooney JF; Smith BP; Walker F; Leon JM
J Pediatr Orthop; 2000; 20(1):108-15. PubMed ID: 10641699
[TBL] [Abstract][Full Text] [Related]
5. Use of botulinum toxin type A in children with cerebral palsy.
Nolan KW; Cole LL; Liptak GS
Phys Ther; 2006 Apr; 86(4):573-84. PubMed ID: 16579673
[No Abstract] [Full Text] [Related]
6. Use of a dynamic foot pressure index to monitor the effects of treatment for equinus gait in children with cerebral palsy.
Bennett D; Walsh M; O'Sullivan R; Gallagher J; O'Brien T; Newman CJ
J Pediatr Orthop; 2007; 27(3):288-94. PubMed ID: 17414011
[TBL] [Abstract][Full Text] [Related]
7. Botulinum A toxin for treatment of lower limb spasticity in cerebral palsy: gait analysis in 49 patients.
Papadonikolakis AS; Vekris MD; Korompilias AV; Kostas JP; Ristanis SE; Soucacos PN
Acta Orthop Scand; 2003 Dec; 74(6):749-55. PubMed ID: 14763710
[TBL] [Abstract][Full Text] [Related]
8. Neuronox versus BOTOX for spastic equinus gait in children with cerebral palsy: a randomized, double-blinded, controlled multicentre clinical trial.
Kim K; Shin HI; Kwon BS; Kim SJ; Jung IY; Bang MS
Dev Med Child Neurol; 2011 Mar; 53(3):239-44. PubMed ID: 21087238
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial to compare two botulinum toxin injection techniques on the functional improvement of the leg of children with cerebral palsy.
Kaishou Xu ; Tiebin Yan ; Jianning Mai
Clin Rehabil; 2009 Sep; 23(9):800-11. PubMed ID: 19482892
[TBL] [Abstract][Full Text] [Related]
10. Cortical somatosensory evoked potentials and spasticity assessment after botulinum toxin type A injection in children with cerebral palsy.
Boćkowski L; Okurowska-Zawada B; Sobaniec W; Kułak W; Sendrowski K
Adv Med Sci; 2007; 52 Suppl 1():171-5. PubMed ID: 18229658
[TBL] [Abstract][Full Text] [Related]
11. [Botulinum toxin type A in the treatment plan for cerebral palsy].
Strobl W
Wien Klin Wochenschr; 2001; 113 Suppl 4():30-5. PubMed ID: 15506050
[TBL] [Abstract][Full Text] [Related]
12. Treating spastic equinus foot from cerebral palsy with botulinum toxin type A: what factors influence the results?: an analysis of 189 consecutive cases.
Pascual-Pascual SI; Pascual-Castroviejo I; Ruiz PJ
Am J Phys Med Rehabil; 2011 Jul; 90(7):554-63. PubMed ID: 21765274
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of the spastic drop foot with botulinum toxin type A in adult patients].
Voller B; Földy D; Hefter H; Auff E; Schnider P
Wien Klin Wochenschr; 2001; 113 Suppl 4():25-9. PubMed ID: 15506049
[TBL] [Abstract][Full Text] [Related]
14. Effect of multilevel botulinum toxin a and comprehensive rehabilitation on gait in cerebral palsy.
Scholtes VA; Dallmeijer AJ; Knol DL; Speth LA; Maathuis CG; Jongerius PH; Becher JG
Pediatr Neurol; 2007 Jan; 36(1):30-9. PubMed ID: 17162194
[TBL] [Abstract][Full Text] [Related]
15. [Botulinum toxin: a new dimension for spasticity].
Reichel G
MMW Fortschr Med; 2007 May; 149 Suppl 2():65-9. PubMed ID: 17724971
[TBL] [Abstract][Full Text] [Related]
16. Treatment of spastic equinus gait with botulinum toxin A: Does dose matter? Analysis of a clinical cohort.
Sätilä HK; Pietikäinen T; Lehtonen-Räty P; Koivikko M; Autti-Rämö I
Neuropediatrics; 2006 Dec; 37(6):344-9. PubMed ID: 17357036
[TBL] [Abstract][Full Text] [Related]
17. Short-term effects of "botulinum toxin a" as treatment for children with cerebral palsy: kinematic and kinetic aspects at the ankle joint.
Galli M; Crivellini M; Santambrogio GC; Fazzi E; Motta F
Funct Neurol; 2001; 16(4):317-23. PubMed ID: 11853322
[TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin and cerebral palsy: time for reflection?
Gough M; Fairhurst C; Shortland AP
Dev Med Child Neurol; 2005 Oct; 47(10):709-12. PubMed ID: 16174320
[TBL] [Abstract][Full Text] [Related]
19. [Botulinum toxin Type A. Indications and results].
Póo P; López-Casas JA; Galván-Manso M; Aquino-Fariña L; Terricabras-Carol L; Campistol J
Rev Neurol; 2003 Jul 1-15; 37(1):74-80. PubMed ID: 12861515
[TBL] [Abstract][Full Text] [Related]
20. Computerized gait analysis of botulinum toxin treatment in children with cerebral palsy.
Galli M; Cimolin V; Valente EM; Crivellini M; Ialongo T; Albertini G
Disabil Rehabil; 2007 Apr; 29(8):659-64. PubMed ID: 17453987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
